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Methods: SLNs consist of a solid lipid matrix where the drug was incorporated. Surfactants of GRAS grade were used to avoid aggregation and to 
stabilize the SLNs. DST-SLNs formulations of varying concentrations were prepared by high-speed homogenization technique and evaluated for 
drug excipients compatibility study, poly-dispersity index, particle size analysis, surface morphology, zeta potential, and drug release features.  
The aim of present work was to formulate and evaluate Dasatinib (DST) loaded solid lipid nanoparticles (SLNs) as a potential anticancer 
drug delivery system by enhancing its solubility.  
Results: It was observed that DST-SLNs with optimum quantities of poloxomer: lecithin ratio showed 88.06% drug release in 6h with good 
entrapment efficiency of 76.9±0.84 %. Particle size, Polydispersity index, zeta potential and drug entrapment efficiency for the optimized 
formulation was found to be optimum. Stability studies revealed that the entrapment efficiency of the SLN dispersion stored in 4 °C was stable. 
Conclusion: Thus, it can be concluded that the formulations of DST loaded SLNs are suitable carriers for improving the solubility and dissolution 
related problems. 
Keywords: 
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Although a large number of new drug molecules with varied 
therapeutic potentials have been discovered in the recent decade, 
yet most of them are still in the developmental process. This can be 
attributed to the limited aqueous solubility which governs the 
bioavailability of such drug molecules. One amongst them is 
Dasatinib (DST). Hence, there is a requisite for a technology-based 
product (formulation) in order to overcome such issues without 
compromising on the therapeutic response. DST is very poorly 
soluble in water [1], and maximum solubility in plain water is 
estimated to be about 10 µM [2]. Low aqueous solubility and poor 
dissolution of DST results into poor and variable bioavailability [1-
3]. Oral bioavailability of DST is ranging from 14% to 34% [3]. Poor 
drug solubility makes it very difficult to perform high-throughput 
screening of products for potential drug effects. Therefore, there is 
an urgent need for intelligent drug formulations to achieve sufficient 
bioavailability of DST. Many different approaches have been 
developed to overcome the solubility problem of poorly soluble 
drugs including solubilization, inclusion compounds and 
complexation. An alternative to these methods developed was drug-
nanoparticle formulation. 
INTRODUCTION 
The emerging field of nanotechnology seeks to exploit distinct 
technological advantages of nanoscience. The booming 
nanotechnologies are supported by massive state investments in 
many countries. Companies worldwide are producing consumer 
products with growing “nano”-content. Significant effort has been 
devoted to develop biocompatible nanosystems such as 
nanoparticles, nanocapsules, micellar systems, and conjugates. The 
basic advantage of nanonization is the increase in surface area and 
the concentration gradient of these poorly soluble compounds 
followed by an increased dissolution rate of the compounds 
according to the Noyes-Whitney equation. In addition, the saturation 
solubility is also increased after nanonization [4]. All these may 
benefit oral bioavailability of poorly soluble drugs by enhancing 
drug transport through gut wall into the systemic circulation [5]. 
SLNs have been reported as an alternative drug delivery system to 
traditional polymeric nanoparticles (Mu¨ hlen et al. 1998; Mehnert 
and Mader 2001). Nanoparticles are in the submicron size range 
(50–1000 nm) and are composed of physiologically tolerated lipid 
components; at room temperature, the particles are in the solid state 
(Schwarz et al. 1993; Mu¨ ller and Lucks 1996). SLNs combine the 
advantages of poly-meric nanoparticles, fat emulsions and 
liposomes (Schwarz and Mehnert 1999). They can be produced on a 
large industrial scale by high-pressure homogenization (Dingler and 
Gohla 2002), are toxicologically highly acceptable like emulsions and 
liposomes, produce sustained release due to their solid matrix, similar 
to polymeric nanoparticles, and can effectively target specific tissues 
after parenteral administration (Cavalli et al. 1999; Yang et al. 1999). 
In this study, SLNs were employed to investigate the enhancement of 
the absorption and bioavailability of poorly soluble drugs. 
SLNs have been reported as an alternative drug delivery system to 
traditional polymeric nanoparticles (Mu¨ hlen et al. 1998; Mehnert 
and Mader 2001). Nanoparticles are in the submicron size range 
(50–1000 nm) and are composed of physiologically tolerated lipid 
components; at room temperature, the particles are in the solid state 
(Schwarz et al. 1993; Mu¨ ller and Lucks 1996). SLNs combine the 
advantages of polymeric nanoparticles, fat emulsions, and liposomes 
(Schwarz and Mehnert 1999). They can be produced on a large 
industrial scale by high-pressure homogenization (Dingler and 
Gohla 2002), are toxicologically highly acceptable like emulsions and 
liposomes, produce sustained release due to their solid matrix, 
similar to polymeric nanoparticles, and can effectively target specific 
tissues after parenteral administration (Cavalli et al. 1999; Yang et 
al. 1999). In this study, SLNs were employed to investigate the 
enhancement of the absorption and bioavailability of poorly soluble 
drugs. SLNs have been reported as an alternative drug delivery 
system to traditional polymeric nanoparticles (Mu¨ hlen et al. 1998; 
Mehnert and Mader 2001). Nanoparticles are in the submicron size 
range (50–1000 nm) and are composed of physiologically tolerated 
lipid components; at room temperature, the particles are in the solid 
state (Schwarz et al. 1993; Mu¨ ller and Lucks 1996). SLNs combine 
the advantages of polymeric nanoparticles, fat emulsions and 
liposomes (Schwarz and Mehnert 1999). They can be produced on a 
large industrial scale by high-pressure homogenization (Dingler and 
Gohla 2002), are toxicologically highly acceptable like emulsions and 
liposomes, produce sustained release due to their solid matrix, 
similar to polymeric nanoparticles, and can effectively target specific 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 10, Issue 12, 2018 
Begum et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 12, 14-20 
 
15 
tissues after parenteral administration (Cavalli et al. 1999; Yang et 
al. 1999). In this study, SLNs were employed to investigate the 
enhancement of the absorption and bioavailability of poorly soluble 
drugs. 
Solid lipid nanoparticles (SLNs) have been reported as an alternative 
drug delivery system to traditional polymeric nanoparticles. 
Nanoparticles are in the submicron size range (50–1000 nm) and 
are composed of physiologically tolerated lipid components, and at 
room temperature, the particles are in the solid state. SLNs combine 
the advantages of polymeric nanoparticles, fat emulsions, and 
liposomes. They can be produced on a large industrial scale by high-
pressure homogenization. SLNs are toxicologically highly acceptable 
like emulsions and liposomes, produce sustained release due to their 
solid matrix, similar to polymeric nanoparticles, can effectively 
target specific tissues after parenteral administration and found to 
be the effective tool in improving the oral bioavailability of poorly 
soluble drugs [6, 7]. In this study, SLNs were employed to investigate 
the enhancement of the solubility and dissolution behaviour of the 
poorly water-soluble drug, DST as well as DST loaded SLNs may be 
exploited as targeted delivery systems that can provide higher 
specificity to cancer cells with no/minimal effect on normal cells. 
MATERIALS AND METHODS 
Materials 
DST was obtained as gift sample from Aizant laboratories, 
Hyderabad. Stearic acid, ethanol, chloroform, DMSO were obtained 
from SD Fine Chemicals Pvt Ltd, Mumbai. Lecithin and poloxomer 
188 were obtained from Dr, Reddy’s Laboratories, Hyderabad as gift 
samples. All the other ingredients used were of analytical grade.  
An analytical method for DST 
Accurately weighed quantity of DST was dissolved in little of DMSO 
followed by pH 4 Acetate buffer and further dilutions were done using 
pH 4 Acetate buffer to get the standard working solutions of 2 to 9 
µg/ml. The solutions were measured with absorbance using UV 
spectrophotometer at 326 nm against the blank. Calibration curve was 
constructed by plotting the graph between absorbance vs. concentration. 
Preparation of DST loaded SLNs (homogenization)  
DST Loaded SLNs was prepared by making an organic phase 
containing the drug, stearic acid, and lecithin at varying ratios into 
ethyl alcohol (10 ml, 93% V/V). The aqueous phase was prepared by 
dissolving variable amounts of poloxamer 188 in water (50 ml).  
The organic phase was dropped into the aqueous phase at a constant 
rate under homogenization at 800rpm for 15 min using a high sheer 
homogenizer. The resulting suspension was immediately 
transferred to cold distilled water (50 ml) and kept in an ice bath 
while stirring at 800rpm for 1h. Then the suspension was 
centrifuged at 5000rpm for 1h. The precipitate was washed twice 
with double-distilled water and suspended in mannitol solution 
(10 % w/v). The suspension was lyophilized and kept at a constant 
temperature of 4 °C for further use [8]
  
. 
Table 1: Composition of DST loaded SLN
S. No. 
s 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Dasatinib 10 10 10 10 10 10 10 10 10 
2 Lecithin 50 50 50 50 25 12.5 25 - 25 
3 Poloxomer 188 1 2 3 4 3 3 2 3 - 
4 Stearic acid 100 100 100 100 100 100 100 100 100 
5 Ethanol(ml) 4 4 4 4 4 4 4 4 4 
6 Chloroform 6 6 6 6 6 6 6 6 6 




The solubility of DST was determined in various solvents such as 
acetone, acetonitrile, ethanol, methanol, DMSO, and chloroform 
using the shake flask method.  
Evaluation of DST loaded SLNs 
FTIR compatibility studies 
FTIR spectrum was recorded over the region of 400 to 4000 cm-1
Determination of zeta potential 
 for 
pure drug alone and along with excipients in BRUKER FTIR 
Instrument using KBr pellet technique. 
The Zeta Master apparatus (Malvern Instruments, Malvern.) was 
used to calculate zeta potential by determining the electrophoretic 
mobility of the optimized formulation. It was obtained by 
performing an electrophoresis experiment on the sample and 
measuring the velocity of particles. There exists an electrical double 
layer at the interface between solid particle surface and the 
surrounding liquid medium. The inner electrical layer is tightly 
bound to the surface whereas the outer layer is loosely attached due 
to electrostatic forces and Brownian motion developed. The 
glycerosomal particle moves in the liquid medium along with its 
associated charges as a unit. The ionic potential at the surface 
between this unit and the surrounding medium is called as Zeta 
potential, and it is measured in millivolts [9].  
Particle size and morphology  
Scanning electron microscopy was used to verify the uniformity of 
particle shape and size [9]. The lyophilized nanoparticles were 
dropped onto double-sided carbon tape. They were then vacuum-
coated for 45 seconds with a platinum mixture and examined for 
morphology with a FE-SEM (JEOL JSM7500, Thermo Scientific) at 5 kV. 
Drug entrapment efficiency 
The percentage of drug entrapped was determined by centrifugation 
method. 10 ml of aqueous suspension was centrifuged at 10,000 
rpm for 20 min. The amount of drug was detected in the supernatant 
and in the pellet. The entrapment efficiency was calculated using the 
following formula [10]  
 
In vitro diffusion study 
In vitro release studies were carried out by using modified diffusion 
assembly USP XXI. The Semipermeable membrane was conditioned by 
soaking in PH4 Acetate buffer for 24 h. The donor compartment consists 
of a glass tube with an inner diameter of 2.5 cm, open at both ends and 
tied at with dialysis membrane. The DST loaded SLNs, equivalent to 10 
mg of DST was taken in this compartment and placed in a beaker 
containing 250 ml of pH 4 acetate buffer, which was magnetically stirred 
at moderate speed (200 rpm) at a temperature of 37 °C. 2 ml sample was 
withdrawn and same volume of medium was replaced at predetermined 
interval and was assayed UV Spectrophotometrically at 326 nm against 
pH 4 acetate buffer as blank. The in vitro release profiles of these 
formulations were then compared with the pure drug [11]. 
Stability studies 
Stability study was conducted for the formulation F5 having high 
entrapment efficiency by storing the formulation at two different 
temperatures, 4 °C and 25±2 °C and the drug content was estimated 
every 15 d, to find out any change in the entrapment efficiency of the 
SLNs [12]. 
Solubility studies 
RESULTS AND DISCUSSION 
The solubility of DST was found to be 200 mg/ml in DMSO. It was 
found to be poorly soluble in water and ethanol. So DMSO was 
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selected as co-solvent to dissolve DST during construction of calibration curve. 
 
 FTIR compatibility studies 
 
Fig. 1: FTIR spectra of DST 
 
 




 FTIR compatibility studies 
FTIR significant peaks 
Reported values Observed values for pure drug (cm-1 Observed values for drug and excipients (cm) -1) 
C-C stretching 1300-400 1362.54 cm- 1281.84 cm-1 
C=O stretching 1700-1600 1436.15 cm-1 1626.73 cm-1 
C-N stretching 1080-1360 1192.64 cm-1 1068.93 cm-1 
N-H stretching 3600-3310 3179 cm-1 3057.59 cm-1 
Aromatic C-H stretching 3200-3000 3187 cm-1 2996.58 cm-1 
Aromatic C-H bending 1000-675 993.92 cm-1 870.30 cm-1 
C-Cl stretching 600-800 485.32 cm-1 558.90 cm-1 
 
 
Fig. 3: Particle size distribution of DST loaded SLNs 
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FT-IR spectroscopic study was carried out to find out drug 
excipients interaction. The characteristic peaks of the drug between 
IR spectrum of DST and drug excipients mixture were identified by 
absorption peaks at 3179 cm-1 (secondary amine N-H stretch), 3187 
cm-1 (=C-H aromatic ring),993.92 cm-1 (C-H bending), 1192.64 cm-
1 (C-N stretch), 1436 cm-1 (C=O stretch) and 1362 cm-1 (C=C) 
stretch, aromatic ring. Thus, FTIR Spectroscopy was employed to 
obtain conformational information about the lipid molecules, and it 
is used to investigate the interactions between lipid, drug and 
excipients thereby confirming that there were no particular 
interactions between them and drug remain intact in the 
formulation. The principal peaks of DST were observed in the 
spectra of the drug and lipids physical mixture indicating no 
interactions had been occurred [13]. 
Particle size analysis 
It measures and relates the size of particles typically in the sub-
micron region by Brownian motion. (Brownian motion is the 
random movement of particles due to the bombardment by the 
solvent molecules that surrounds them). Particle size depends on 
the hardness of the drug, process parameters, and materials used 
such as stabilizers, emulsifying agents, etc. The analysis revealed 
that the SLN produced had a particle size ranging from 94 nm to 800 
nm with a polydispersity index ranging from 0.11 to 0.44. 
Measurement of zeta potential 
The zeta potential of nanoparticles is commonly used to characterize 
the surface charge property of nanoparticles. It reflects the electrical 
potential of particles and is influenced by the composition of the 
particle and the medium in which it is dispersed. Optimized formula 
f5 had good zeta potential values thereby indicating the optimized 
formulation had comparatively effective stability. 
The zeta values of all the formulations were from-67.90 
to+31.75mV. Thus, the range of zeta potential obtained was found to 
be high enough for sufficient electrostatic stabilization. However, the 
wide range of values may be due to the shielding effect of poloxamer 
188 which is at varying concentration, and this acts as a cover for 
the surface charges due to the presence of its hydrophilic corona 
around the nanoparticles. Since poloxamer 188 may offer additional 
steric stabilization for SLN, it is assumed that there was a 
combination of electrostatic and steric stabilization in the 
investigated SLN formulae.  
They showed the formation of small nanoparticles with relatively 
low polydispersity indices. Although there was an insufficient charge 
to stabilize the nanoparticles electrostatically, there was steric 
stabilization due to the added poloxamer [9]. 
 
 
Fig. 4: Zeta potential of DST loaded SLNs 
 
Table 3: Results of p
Formulation code 
article size analysis and zeta potential 
Average particle size (nm) Polydispersity index(PI) Zeta potential(mV) 
F1 309.84 0.17 31.23 
F2 340.89 0.29 39.65 
F3 365.52  0.21 32.98 
F4 400.02 0.17 47.90 
F5 202.60 0.18 31.75 
F6 188.45  0.11 -33.75 
F7 94.58  0.19 -66.16 
 F8  708.53  0.23 -67.90 
 F9 800.36  0.44 -30.23 
 
Scanning electron microscopy  
The particles have moderate uniformity and all the particles were 
discrete entities, shows aggregation of particles after lyophilization 
and these particles was readily re-dispersible. It was clear from the 
image that DST loaded SLNs were near spherical in shape with the 
presence of some particle aggregates. This is particularly because of 
the particle being coated with a surfactant layer.  
Drug entrapment efficiency 
The maximum encapsulation efficiency of 76.9% was found to be 
for F5 containing the optimum amounts of lecithin and poloxamer. 
The encapsulation efficiency was found to below 20.34% and 
15.86% respectively for the formulations that did not contain 
either lecithin (F8) or poloxamer (F9). The combined effect of the 
two independent variables, namely poloxamer 188 (which was 
measured as a percentage) and lecithin (which was measured in 
milligrams), were studied in respect of the encapsulation 
efficiency. The results revealed that increasing the concentration 
of poloxamer 188 had the dominant effect of increasing the 
encapsulation efficiency. It is clear from the data that the 
encapsulation efficiency is directly proportional to the 
concentration of the poloxamer 188, however, this is only the case 
when mixed with lecithin. 
Begum et al. 








 Entrapment efficiency of DST loaded SLNs 










 Data are represented as mean±standard deviation (SD), n=3 
 
Using poloxamer188 without lecithin failed to increase the 
encapsulation efficiency as measured for F8. Conversely, increasing 
the concentration of lecithin, in the presence of poloxamer188, 
increased the encapsulation efficiency. The results indicate that both 
poloxamer and lecithin played a pivotal role in the encapsulation 
efficiency of the drug. However, the concentration of poloxamer was 
more significant in its effects on encapsulation efficiency than 
lecithin. The poloxamer may assist to form the hydrophilic shell 
surrounding the SLN and thus enhances its stability. Lecithin has 
high lipophilicity and is a water-insoluble surfactant. In the present 
study, the addition of poloxamer to the aqueous medium led to the 
formation of a mesh-type network that surrounded the particles and 
prevented the drug from migrating into the aqueous medium. 
However, as proven by the encapsulation efficiency results obtained 
in the absence of poloxamer, the importance of poloxamer with its 
capabilities to entrap the drug within the shell region and to prevent 
their escape was revealed. Our hypothesis postulates that the 
fraction of drug that entered the water when the poloxamer was 
absent is relatively large. Here, we stress the importance of 
poloxamer in stabilizing the SLNs, in addition to the prevention of 
escape of the reversed drug from the SLNs [8]. 
The results showed that the increase in the concentration of the 
surfactant increase drug release from the SLN until an optimum 
concentration after that the drug release was found to be decreased. 
In vitro drug release study 
 
The formulation F5 prepared using optimum amount of lipid and 
surfactant was found to show higher drug release of 88.06% in 6hours. 
When the amount of lecithin was reduced to 50% it did not make any 
considerable differences in drug release. But the further reduction in 
lecithin concentration reduced the drug entrapment efficiency as well 
as drug release (F6). Formulations prepared without lecithin (F8) and 
without poloxamer 188 (F9) showed a drastic reduction in drug 
entrapment efficiency as well as drug release. 
 
Fig. 6: Drug release profile of DST loaded SLNs for formulations from F1 to F4 (n=3; mean±SD) 
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Fig. 7: Drug release profile of DST loaded SLNs for formulations from F5 to F7 (n=3; mean±SD) 
 
 
Fig. 8: Drug release profile of DST loaded SLNs for formulations F8 and F9 (n=3; mean±SD) 
 
Stability studies 
The results revealed that the entrapment efficiency of the SLN 
dispersion stored in 4 °C was found to be stable when compared 
to the SLN dispersion stored in 25 °C±2 °C. This may be due to 
more drug expulsion from the lipid matrices at a higher 
temperature. 
 
Table 5: Results of stability studies of the formulation F5 
Formulation % Drug encapsulation efficiency 
Immediately after preparation 15th 30 Day th Day 
Temperature   4 °C 25 °C±2 °C 4 °C 25 °C±2 °C 
F5 76.9±0.84 76.2±0.67 74.9±0.72 75.3±0.51 72.6±0.34 
Data are represented as mean±standard deviation (SD), n=3. 
 
SLNs have emerged as a promising drug delivery system in recent 
years as its potential is gradually and eventually being realized. 
Many drugs having therapeutic activity are highly lipophilic in 
nature. Incorporation and delivery of such lipophilic active 
ingredients at the drug delivery site/target site has always been a 
concern. It was observed that the homogenization and ultrasound 
dispersion method was a useful method for the successful 
incorporation of the poorly water-soluble drug DST with high 
entrapment efficiency. Furthermore, it could be presumed that if the 
nanometer range particles were obtained, the bioavailability might 
be increased. Hence, we can conclude that SLNs are used as drug 
carriers for lipophilic drugs, to enhance the bioavailability of poorly 
water-soluble drugs through nanoparticles, as a drug delivery 
system. 
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